Last reviewed · How we verify
Other Multikinase inhibitors
Other Multikinase inhibitors is a Small molecule drug developed by Bayer. It is currently in Phase 2 development.
At a glance
| Generic name | Other Multikinase inhibitors |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation (PHASE2)
- An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other Multikinase inhibitors CI brief — competitive landscape report
- Other Multikinase inhibitors updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Other Multikinase inhibitors
What is Other Multikinase inhibitors?
Other Multikinase inhibitors is a Small molecule drug developed by Bayer.
Who makes Other Multikinase inhibitors?
Other Multikinase inhibitors is developed by Bayer (see full Bayer pipeline at /company/bayer).
What development phase is Other Multikinase inhibitors in?
Other Multikinase inhibitors is in Phase 2.
Related
- Manufacturer: Bayer — full pipeline
- Compare: Other Multikinase inhibitors vs similar drugs
- Pricing: Other Multikinase inhibitors cost, discount & access